<DOC>
	<DOCNO>NCT01903356</DOCNO>
	<brief_summary>The primary objective study monitor safety profile Trajenta Duo Korean patient type 2 diabetes mellitus ( T2DM ) routine clinical setting .</brief_summary>
	<brief_title>A Regulatory Requirement Non Interventional Study Monitor Safety Effectiveness Trajenta Duo Type 2 Diabetes Patients Korea</brief_title>
	<detailed_description>Study Design : PMS Observational study</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Potential subjets must meet follow inclusion criterion enter trial : 1 . No previous exposure Trajenta , Trajenta Duo 2 . Should start Trajenta Duo accordance approve label Korea 3 . No current participation clinical trial 4 . No metformin inappropriate due contraindication 5 . Must sign data release consent form Exclusion criterion : Individuals follow characteristic able enter study : 1 . Previous exposure Trajenta , Trajenta Duo 2 . Current participation clinical trial 3 . Patients metformin inappropriate due contraindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>